ArticleDiscover oncology2026
Prognostic evaluation of sarcopenia with radiological and laboratory parameters in geriatric head and neck cancer patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aimed to investigate the effect of sarcopenia on survival by evaluating it with pre-treatment and post-treatment radiological and pre-treatment laboratory parameters in patients in the geriatric age group (≥ 65) who were diagnosed with head and neck cancer and received radiotherapy.
methods74 patients who were diagnosed and received radiotherapy (RT) at Kayseri City Training and Research Hospital between 2015 and 2024 were included in the study. The muscle areas at the C3 vertebra level were measured from the pre-treatment and post-treatment computed tomography images of the patients. These muscle area measurements were translated into L3 vertebral muscle area.
resultsThe median overall survival (mOS) of the patients was 36 months. Skeletal muscle index (SMI) values were calculated and evaluated in three categories as pre-treatment (SMIpre), post-treatment (SMIpost) and pre-treatment and post-treatment difference (SMIdiff). While the mOS value of the SMIdiff < 0.46 group could not be accessed, the mOS value of the > 0.46 group was 59 months (p = 0.074). In multivariate Cox regression analysis, independent factors affecting survival were determined as SMIdiff, lymph node involvement, and RT intention (p values: 0.027, 0.006, and 0.047 respectively).
conclusionsThe importance of nutrition both before and during treatment in this age group, which is more prone to malnutrition, is supported by our study, which has a limited number of patients. To the best of our knowledge, the effect of SMIdiff value on survival before and after treatment and the evaluation of PNI in patients with geriatric head and neck cancer are shown for the first time in the literature.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.